Page 1

f 23andMe 23and Me Reports FY2022 Second Quarter Financial Results November 10 , 2021 Second quarter revenue of $ 55 million Recent addition of telemedicine platform further advances vision of individualized primary care that empowers consumers to live healthier lives SUNNYVALE , Calif . , Nov. 10 , 2021 ( GLOBE NEWSWIRE ) -- 23andMe Holding Co. ( Nasdaq : ME ) ( " 23andMe " ) , a leading consumer genetics and research company , today reported its financial results for the second quarter ( “ Q2 " ) of its fiscal year 2022 ( " FY2022 " ) , which ended September 30 , 2021 . " With the addition of telemedicine and pharmacy services to our Personal Genome Service products and services , we significantly advance our efforts to provide consumers with convenient access to personalized , proactive and genetically - based health services , " said Anne Wojcicki , CEO and Co - Founder of 23andMe . " We are also pleased with the progress of our therapeutics pipeline . Our partner , GSK , expects to report clinical data from the CD96 program in 2022. In addition , we expect to start a clinical trial with our wholly owned P006 program by the end of fiscal year 2022. " Recent Highlights • Completed the acquisition of Lemonaid Health , Inc ( " Lemonaid Health " ) , an on - demand platform for accessing medical care and pharmacy services online • Expanded customer database to 11.9 million genotyped customers • Launched three new reports for customers subscribed to 23and Me + , a membership service that offers insights and features to give members even more actionable information to live healthier lives . These new reports use machine learning to create a statistical model that estimates a person's likelihood of developing a specific condition . The new reports released in the second quarter were : o A gallstones report that uses 6,950 genetic markers , along with a customer's ethnicity and sex , to estimate a person's likelihood of developing gallstones o An HDL cholesterol report that uses 15,825 genetic markers , along with a customer's ethnicity and sex , to estimate the likelihood of an individual having low HDL ( or " good " ) cholesterol o A gestational diabetes report that uses a person's ethnicity and more than 6,000 genetic variants associated with developing gestational diabetes mellitus to estimate a person's likelihood of developing this condition . • Reported on key genetic research findings in Q2 , including findings regarding COVID - 19 vaccines reactions , health implications of e - cigarette use and genes associated with longer reproductive lifespan in women • Added a new ancestry analysis , which offers additional insights into some customers ' indigenous genetic ancestry from North America . • Added a new board member : Sandra R. Hernández , President and CEO of the California Health Care Foundation " We made good progress on advancing our consumer health services segment with product enhancements , such as new genetic health risk reports and the acquisition of Lemonaid Health . These additions are aimed at extending our personalized and customer - centric philosophy to help people live healthier lives , " said Steve Schoch , Chief Financial Officer of 23andMe . " While we will be updating guidance next quarter to include the effects of the Lemonaid Health acquisition , currently , our prior full - year guidance for 23andMe , excluding the consolidation of Lemonaid Health , is consistent with our current view of expected performance . " FY2022 Second Quarter Financial Results Total revenue for the three- and six - months ended September 30 , 2021 , was $ 55 million and $ 114 million , respectively , representing increases of 7 % and 15 % , respectively , for the same periods in the prior year . This revenue growth was primarily due to higher Personal Genome Service ( " PGS " ) kit sales and subscriptions , a service that is still in its first year post launch . Consumer services revenue represented approximately 81 % of total revenue for the three and six months ended September 30 , 2021 , and research services revenue , substantially all derived from the collaboration with GSK , accounted for approximately 19 % of total revenue . Operating expenses for the three- and six - months ended September 30 , 2021 were $ 74 million and $ 147 million , respectively , compared to $ 61 million and $ 120 million for the same periods in the prior year . The increase in operating expenses was primarily attributable to the increase in research and development expenses related to our therapeutics programs along with sales and marketing expenses intended to grow the consumer business . Net loss for the three- and six - months ended September 30 , 2021 was $ 17 million and $ 59 million , respectively , compared to net losses of $ 36 million and $ 72 million for the same periods in the prior year . The improvement in net loss was primarily driven by changes in fair value of warrant liabilities of $ 30 million and $ 29 million , respectively , for the three and six months ended September 30 , 2021. It is anticipated that there could be significant changes in the fair value of the warrant liabilities from quarter to quarter . Total Adjusted EBITDA ( as defined below ) for the three and six months ended September 30 , 2021 was $ ( 30 ) million and $ ( 57 ) million , respectively , compared to $ ( 20 ) million and $ ( 40 ) million for the same periods in the prior year . The decrease in total Adjusted EBITDA was driven primarily by an increase in research and development expenses related to our therapeutics programs and sales and marketing expenses designed to grow the